Factors Affecting the Price of ILARIS

Canakinumab (ILARIS)’s price is shaped by multiple factors. High R&D costs for developing this interleukin-1β inhibitor, used in rare conditions like cryopyrin-associated periodic syndromes and cardiovascular diseases, drive pricing due to extensive clinical trials. Novartis’ patent protection grants market exclusivity, enabling premium rates. 

Production complexities, including biologic manufacturing and strict quality control for injectable formulations, add to costs. Limited patient populations for rare diseases and regional healthcare policies (e.g., orphan drug subsidies, insurance coverage) also influence final prices paid by patients.